Research Area: Cell engineering & therapy
Development Stage: Optimization
Goal: Identify T cell cytokine production differences with varied bioprocessing methods
to follow our data >[/ce_button]
More robust polyfunctional response of CD4+ or CD8+ CAR-T cell products CD19 or CD22 with the modified manufacturing method (MM) compared to the original manufacturing method (OM).
Data demonstrates that the modified CD19/CD22 bispecific CAR-T cell manufacturing method (MM), which terminated T cell activation/transduction by culture day 3, resulted in reproducible and robust CAR-T cell production, even in the relatively more sensitive patient cells (left).1
to learn more >[/ce_button]
Significantly higher viable TNC, Fold Expansion, Viability, Final CD3% and Transduction Efficiency in products manufactured using the MM compared to OM. Comparable CD4/CD8 ratios across the two methods.
All products using the MM met product release criteria. In addition, final product dose requirements were consistently met by culture day 7 when using the MM, augmenting process efficiency. 1